Gilead punts hep B drug as GlobeIm­mune joins the (dead qui­et) ranks of zom­bie biotechs

GlobeIm­mune has joined a group of the walk­ing dead in biotech. And for a com­pa­ny that has been part­nered with the likes of Cel­gene and Gilead, the fall from grace has been hard and painful.

Af­ter Thurs­day’s mar­ket close the biotech an­nounced that Gilead has re­turned rights to GS-4774, 6 months af­ter the he­pati­tis B treat­ment failed a Phase II study. CEO Tim­o­thy Rodell, who was still hold­ing out hope for GS-4774 last May, has re­signed. Four mem­bers of the board — J. William Frey­tag, Au­gus­tine J. Lawlor, Dan J. Mitchell and S. Ed­ward Tor­res — fol­lowed him out the door. And the com­pa­ny is giv­ing up its 40,000 square foot HQ in Louisville, CO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER